The Goa 2.0 NBS Program was launched in August 2018, which focuses on screening all neonates from government hospitals for six disorders, namely CH, CAH, G6PD, galactosemia, galactose-1-phosphate uridyl transferase (GALT), biotinidase, and CF [8]. This evidence concerns the gene G6PD and classic galactosemia.